Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL4861530

COc1ccc(Cc2ccccc2)cc1OC.N

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.77
LTA4H P09960 2/20 0.58
LMNA P02545 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
MAPT P10636 1/20 0.55
ALDH1A1 P00352 2/20 0.53
GAA P10253 1/20 0.53
ATM Q13315 2/20 0.53
POLB P06746 2/20 0.53
ABCB1 P08183 1/20 0.53
ABCG2 Q9UNQ0 1/20 0.53
KDM4E B2RXH2 1/20 0.52
TTR P02766 1/20 0.51
EBP Q15125 2/20 0.50
SIGMAR1 Q99720 2/20 0.50
PPARG P37231 1/20 0.50
PPARD Q03181 1/20 0.50
PPARA Q07869 1/20 0.50
TMEM97 Q5BJF2 1/20 0.50
LDHA P00338 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL83495 0.98 CA2 (0.80) CA2LTA4HLMNASMN1; SMN2MAPT
SCHEMBL2095593 0.88 CA2 (1.00) CA2LMNASMN1; SMN2ALDH1A1GAA
SCHEMBL29449205 0.84 CA2 (0.91) CA2LMNASMN1; SMN2ALDH1A1GAA
SCHEMBL28164756 0.84 CA2 (0.91) CA2LMNASMN1; SMN2ALDH1A1GAA
SCHEMBL14769223 0.83 CA2 (0.57) CA2LTA4HLMNASMN1; SMN2MAPT
SCHEMBL9450898 0.83 CA2 (0.57) CA2LTA4HSMN1; SMN2ALDH1A1GAA
SCHEMBL2090122 0.83 CA2 (0.57) CA2LTA4HALDH1A1GAA
SCHEMBL8604705 0.82 CYP19A1 (0.70) CA2ALDH1A1ATMPOLBABCB1
SCHEMBL30173445 0.82 CYP19A1 (0.70) CA2ALDH1A1ATMPOLBABCB1
SCHEMBL11282921 0.81 CA2 (0.71) CA2LMNAALDH1A1GAAATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7329761-B2 Substituted imides CELGENE CORPORATION (US) 2008-02-12 US disclosed
EP-0800514-B1 SUBSTITUTED IMIDES AS TNF INHIBITORS CELGENE CORP (US) 2006-08-23 EP disclosed
US-20050090516-A1 Novel substituted imides MULLER GEORGE W (US) 2005-04-28 US disclosed
US-6844359-B2 Substituted imides CELGENE CORPORATION (US) 2005-01-18 US disclosed
US-20020143027-A1 Novel substituted imides MULLER GEORGE W (US) 2002-10-03 US disclosed
US-6429221-B1 INHIBITORS OF TUMOR NECROSIS FACTOR; USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, AND RETROVIRUS REPLICATION CELGENE CORPORATION 2002-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143027-A1 Novel substituted imides TNF, MIF, TNFRSF1A CA2 4444/4885LTA4H 3859/4885LMNA 3145/4885
US-20050090516-A1 Novel substituted imides TNF, MIF, TNFRSF1A CA2 4349/4885LTA4H 3920/4885LMNA 3166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.